16to5 - GettyImages-856593880_green

Podcasts

The LathamTECH Podcast

In each episode of the LathamTECH Podcast, we survey the latest trends emerging from the world of tech and explore their impacts on your company — both the opportunities and the risks. 

Watch here or subscribe via Apple PodcastSpotify, or YouTube, or wherever you find your podcasts.

Connected With Latham

In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.

Listen here or subscribe via Apple PodcastsSpotify, or anywhere else you listen to podcasts.

The Growth Rocketship Series

Drug Pricing Series

Digitally rendered gel capsule filled with multicolor spheres.
June 06, 2025

Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.

Shiny transparent capsule filled with colorful spheres
March 12, 2025

Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

Shiny transparent capsule filled with colorful spheres
November 26, 2024

Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

Shiny transparent capsule filled with colorful spheres
February 01, 2024

Drug Pricing: A Look Ahead at Trends for 2024

Listen to this “lightning round” to hear how the policy and regulatory environment will likely remain hostile for pharmaceutical manufacturers, and how to address the turbulence that lies ahead.